Suman Adrian Florentin, De Luca Davide, Gaggini Melania, Cucco Francesco
Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.
Biomolecules. 2025 Sep 20;15(9):1346. doi: 10.3390/biom15091346.
Diffuse large B-cell lymphoma (DLBCL) is a molecular and clinical heterogenous entity, and, over the past 30 years, many efforts have been made in trying to dissect this diverseness and identify biomarkers capable of efficiently stratifying DLBCL patients and spotting the ones showing a worse clinical outcome. Despite the achievement in this research field, only a few biomarkers have been validated and introduced in a clinical setting. Among those, approximately 5-15% of DLBCL cases harbor gene translocations, often involving immunoglobulin genes as a translocation partner, and concomitant point mutations, correlating with a poor response to standard therapies. However, given the difficulty in detecting these abnormalities requiring specialized techniques and high-quality specimens, the use of metabolomics (i.e., the study of small metabolites in body fluids and tissues) can offer a useful alternative for the identification of high-risk DLBCL patients. Amino acids (AAs) are metabolites essential in the process of tumorigenesis and can increase immune escape and drug resistance. Therefore, we review the use of metabolomics to improve the diagnosis and prognosis in DLBCL patients in relation to the MYC role in the regulation of amino acid metabolism, as these metabolites may be used as potential biomarkers in a clinical environment.
弥漫性大B细胞淋巴瘤（DLBCL）是一种分子和临床异质性实体，在过去30年里，人们做出了许多努力来剖析这种多样性，并确定能够有效分层DLBCL患者以及识别临床结局较差患者的生物标志物。尽管在该研究领域取得了一定成果，但仅有少数生物标志物得到验证并应用于临床。其中，约5%-15%的DLBCL病例存在基因易位，通常涉及免疫球蛋白基因作为易位伴侣，同时伴有点突变，这与对标准疗法的不良反应相关。然而，鉴于检测这些异常需要专门技术和高质量标本，代谢组学（即研究体液和组织中的小分子代谢物）可为识别高危DLBCL患者提供一种有用的替代方法。氨基酸（AAs）是肿瘤发生过程中必不可少的代谢物，可增强免疫逃逸和耐药性。因此，我们综述了代谢组学在改善DLBCL患者诊断和预后方面的应用，以及MYC在氨基酸代谢调节中的作用，因为这些代谢物可能在临床环境中用作潜在的生物标志物。
